Results 211 to 220 of about 24,893 (251)

Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome. [PDF]

Nephrol Dial Transplant
Ter Avest M, Duineveld C, Bouwmeester RN, Baas LM, van den Heuvel LPWJ, Langemeijer SMC, Wetzels JFM, van de Kar NCAJ, Ter Heine R, CUREiHUS study group .   +9 more
europepmc   +1 more source

Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab. [PDF]

Haematologica
Ardissino G, Angelillo P, Mancuso MC, Griffini S, Grovetti E, Porcaro L, Ria T, Marktel S, Peyvandi F, Luminari S, Ferreri AJM, Merli M, Cugno M.   +12 more
europepmc   +1 more source

Ravulizumab in treatment-naïve patients with atypical hemolytic uremic syndrome: a real-world case series. [PDF]

Drug Target Insights
Livia Maria S, Iacuzzo C, Sciri R, Zacchia M, Iannuzzi M, Marotta P, Vitale P, Taglioni C, Secondulfo F, Palazzetti D, Baccaro R.   +10 more
europepmc   +1 more source

Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance. [PDF]

Clin Exp Nephrol
Ito S, Hataya H, Matsumoto M, Shimono A, Teranishi H, Okuda M, Miyakawa Y, Maruyama S.   +7 more
europepmc   +1 more source

A Case of Atypical Hemolytic Uremic Syndrome With a Complement Factor I Mutation Triggered by a Femoral Neck Fracture. [PDF]

Nephrology (Carlton)
Kano T, Io H, Sasaki Y, Muto M, Muto S, Ogiwara K, Ikeda A, Iwasaki H, Suzuki Y.   +8 more
europepmc   +1 more source

[Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Guo DD, Xiao YX, Wang WR, Deng XL, Huang YH.   +4 more
europepmc   +1 more source

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Kidney International, 2020
Ravulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased elimination half-life, allowing an extended dosing interval from two to eight weeks.
Eric Rondeau, Spero R Cataland, Yoshitaka Miyakawa   +2 more
exaly   +2 more sources

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

New England Journal of Medicine, 2013
F Eitner, Denis Fouqué, Bruno Moulin
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Atypical Hemolytic–Uremic Syndrome

New England Journal of Medicine, 2009
The hemolytic–uremic syndrome, which is characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal impairment, occurs most frequently in young children. Most cases are secondary to infection with Escherichia coli O157:H7 and other Shiga-toxin–producing strains.
Marina Noris, Giuseppe Remuzzi
exaly   +3 more sources

Pathogenesis of Atypical Hemolytic Uremic Syndrome

Journal of Atherosclerosis and Thrombosis, 2019
Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure. aHUS is caused by uncontrolled complement activation in the alternative pathway (AP).
Yoichirô Ikeda, Masaomi Nangaku
exaly   +4 more sources